Citations

Clear

3042 citation(s) found for "Kumar, S".

Risk model‐based management for second primary lung cancer among lung cancer survivors through a validated risk prediction model
Choi, Eunji , Luo, Sophia J. , Ding, Victoria Y. , Kumar, Ashok V., Aredo, Jacqueline V. , Neal, Joel W. , Leung, Ann N. , Hung, Rayjean J., Wakelee, Heather A. , Han, Summer S. , Wampfler, Jason, Neal, Joel W , Yang, Ping , Han, Summer S , Leung, Ann , Wu, Julie , Kumar, Ashok V., Wampfler, Jason A. , Tammemägi, Martin Carl , Wilkens, Lynne R. , Backhus, Leah Monique , Freedman, Neal D. , Hung, Rayjean J., Amos, Christopher I. , Marchand, Loı̈c Le , Cheng, Iona C. , Yang, Ping

Mayo Clinic

Cancer | October 25, 2023 | Volume: 130 | Issue: 5 | Pages: 770-780

10.1002/cncr.35069 | PMID 37877788 Get It

AbstractBackgroundRecent therapeutic advances and screening technologies have improved survival among patients with lung cancer, who are now at high risk of developing second primary lung cancer (SPLC). Recently, an SPLC risk‐prediction model (called SPLC‐RAT) was developed and validated using data from population‐based epidemiological cohorts and clinical trials, but real‐world validation has been lacking. The predictive performance of SPLC‐RAT was evaluated in a hospital‐based cohort of lung cancer survivors.MethodsThe authors analyzed data from 8448 ever‐smoking patients diagnosed with initial primary lung cancer (IPLC) in 1997–2006 at Mayo Clinic, with each patient followed for SPLC through 2018. The predictive performance of SPLC‐RAT and further explored the potential of improving SPLC detection through risk model‐based surveillance using SPLC‐RAT versus existing clinical surveillance guidelines.ResultsOf 8448 IPLC patients, 483 (5.7%) developed SPLC over 26,470 person‐years. The application of SPLC‐RAT showed high discrimination area under the receiver operating characteristics curve: 0.81). When the cohort was stratified by a 10‐year risk threshold of ≥5.6% (i.e., 80th percentile from the SPLC‐RAT development cohort), the observed SPLC incidence was significantly elevated in the high‐risk versus low‐risk subgroup (13.1% vs. 1.1%, p < 1 × 10–6). The risk‐based surveillance through SPLC‐RAT (≥5.6% threshold) outperformed the National Comprehensive Cancer Network guidelines with higher sensitivity (86.4% vs. 79.4%) and specificity (38.9% vs. 30.4%) and required 20% fewer computed tomography follow‐ups needed to detect one SPLC (162 vs. 202).ConclusionIn a large, hospital‐based cohort, the authors validated the predictive performance of SPLC‐RAT in identifying high‐risk survivors of SPLC and showed its potential to improve SPLC detection through risk‐based surveillance.Plain Language Summary Lung cancer survivors have a high risk of developing second primary lung cancer (SPLC). However, no evidence‐based guidelines for SPLC surveillance are available for lung cancer survivors. Recently, an SPLC risk‐prediction model was developed and validated using data from population‐based epidemiological cohorts and clinical trials, but real‐world validation has been lacking. Using a large, real‐world cohort of lung cancer survivors, we showed the high predictive accuracy and risk‐stratification ability of the SPLC risk‐prediction model. Furthermore, we demonstrated the potential to enhance efficiency in detecting SPLC using risk model‐based surveillance strategies compared to the existing consensus‐based clinical guidelines, including the National Comprehensive Cancer Network.
Mode of Progression in Smoldering Multiple Myeloma: A study of 406 patients
Rajkumar, S. Vincent , Abdallah, Nadine , Kumar, Shaji , Cook, Joselle , Binder, Moritz , Kapoor, Prashant , Gertz, Morie A. , Lacy, Martha Q. , Hayman, Suzanne R. , Kourelis, Taxiarchis , Warsame, Rahma , Bergsagel, P. Leif , Bergsagel, P. Leif , Rajkumar, S Vincent , Kumar, Shaji K , Cook, Joselle M , Binder, Moritz , Kapoor, Prashant , Dispenzieri, Angela , Gertz, Morie A , Lacy, Martha, Buadi, Francis K , Dingli, David , Lin, Yi , Kourelis, Taxiarchis , Lakshman, Arjun , Dispenzieri, Angela , Buadi, Francis K. , Dingli, David , Lin, Yi

Mayo Clinic

No container title available | October 23, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3378634/v1 | PMID 37961238 Get It

Abstract The approach to patients with high-risk smoldering multiple myeloma (SMM) varies among clinicians; while some advocate early intervention, others reserve treatment at progression to multiple myeloma (MM). We aimed to describe the myeloma-defining events (MDEs) and clinical presentations leading to MM diagnosis among SMM patients seen at our institution. We included 406 patients diagnosed with SMM between 2013-2022, seen at Mayo Clinic, Rochester, MN. The 2018 Mayo 20/2/20 criteria were used for risk stratification. Median follow-up was 3.9 years. Among high-risk patients who did not receive treatment in the SMM phase (n=71), 51 progressed by last follow-up; the MDEs included: bone lesions(37%), anemia(35%), hypercalcemia(8%), and renal failure(6%); 24% met MM criteria based on marrow plasmacytosis (≥60%) and/or free light chain ratio (>100); 45% had clinically significant MDEs (hypercalcemia, renal insufficiency, and/or bone lesions). MM diagnosis was made based on surveillance labs/imaging(45%), testing obtained due to provider suspicion for progression(14%), bone pain(20%), and hospitalization/ED presentations due to MM complications/symptoms(4%). The presentation was undocumented in 14%. A high proportion (45%) of patients with high-risk SMM on active surveillance develop end-organ damage at progression. About a quarter of patients who progress to MM are not diagnosed based on routine interval surveillance testing.
Neuropathologic evaluation of cerebrovascular disease in patients with rheumatoid arthritis
Larsen, Rachel A. , Constantopoulos, Eleni , Kodishala, Chanakya , Lovering, Edward , Hulshizer, Cassondra A., Lennon, Ryan J. , Crowson, Cynthia S. , Nguyen, Aivi T. , Myasoedova, Elena , Crowson, CS , Myasoedova, Elena , Nguyen, Aivi T , Kumar, Rakesh

Mayo Clinic

Rheumatology | October 23, 2023 | Volume: 62 | Issue: SI3 | Pages: SI296-SI303

10.1093/rheumatology/kead396 | PMID 37871918 Get It

Abstract Objectives Active RA has been associated with an increased risk of both cardiovascular and peripheral vascular disease. We aimed to compare cerebrovascular changes in patients with and without RA, both with and without a neuropathologic diagnosis of neurodegenerative disease. Methods Patients with RA (n = 32) who died and underwent autopsy between 1994 and 2021 were matched to non-RA controls (n = 32) on age, sex and level of neurodegenerative proteinopathy. Routine neuropathologic examination was performed at the time of autopsy. Cerebrovascular disease severity was evaluated using modified Kalaria and Strozyk scales. Clinical dementia diagnoses were manually collected from patients’ medical records. Results Prior to death, 15 (47%) RA patients and 14 (44%) controls were diagnosed with dementia; 9 patients in each group (60% and 64%, respectively) had Alzheimer’s disease. The prevalence of cerebral amyloid angiopathy, microinfarcts, infarcts or strokes was found to be similar between groups. Patients with RA were more likely to have more severe vascular changes in the basal ganglia by Kalaria scale (P = 0.04), but not in other brain areas. There were no significant differences in the presence of large infarcts, lacunar infarcts or leukoencephalopathy by Strozyk scale. Among patients with RA and no clinical diagnosis of dementia, the majority had mild–moderate cerebrovascular abnormalities, and a subset of patients had Alzheimer’s disease neuropathologic changes. Conclusion In this small series of autopsies, patients with and without RA had largely similar cerebrovascular pathology when controlling for neurodegenerative proteinopathies, although patients with RA exhibited more pronounced cerebrovascular disease in the basal ganglia.
Divergent Skeletal Muscle Metabolomic Signatures of Different Exercise Training Modes Independently Predict Cardiometabolic Risk Factors
Kumar, Arathi Prabha, Dasari, Surendra , Klaus, Katherine A. , Nair, K. Sreekumaran , Pataky, Mark W, Kumar, A Aneesh, Nair, K Sreekumaran , Asokan, Aneesh K , Pataky, Mark W , Gaul, David A. , Moore, Samuel G. , Robinson, Matthew M. , Kumar, Ashok , Fernández, Facundo Machado

Mayo Clinic

Diabetes | October 20, 2023 | Volume: 73 | Issue: 1 | Pages: 23-37

10.2337/db23-0142 | PMID 37862464 Get It

We investigated the link between enhancement of SI (by hyperinsulinemic–euglycemic clamp) and muscle metabolites after 12 weeks of aerobic (high-intensity interval training [HIIT]), resistance training (RT), or combined training (CT) exercise in 52 lean healthy individuals. Muscle RNA sequencing revealed a significant association between SI after both HIIT and RT and the branched-chain amino acid (BCAA) metabolic pathway. Concurrently with increased expression and activity of branched-chain ketoacid dehydrogenase enzyme, many muscle amino metabolites, including BCAAs, glutamate, phenylalanine, aspartate, asparagine, methionine, and γ-aminobutyric acid, increased with HIIT, supporting the substantial impact of HIIT on amino acid metabolism. Short-chain C3 and C5 acylcarnitines were reduced in muscle with all three training modes, but unlike RT, both HIIT and CT increased tricarboxylic acid metabolites and cardiolipins, supporting greater mitochondrial activity with aerobic training. Conversely, RT and CT increased more plasma membrane phospholipids than HIIT, suggesting a resistance exercise effect on cellular membrane protection against environmental damage. Sex and age contributed modestly to the exercise-induced changes in metabolites and their association with cardiometabolic parameters. Integrated transcriptomic and metabolomic analyses suggest various clusters of genes and metabolites are involved in distinct effects of HIIT, RT, and CT. These distinct metabolic signatures of different exercise modes independently link each type of exercise training to improved SI and cardiometabolic risk. Article Highlights We aimed to understand the link between skeletal muscle metabolites and cardiometabolic health after exercise training. Although aerobic, resistance, and combined exercise training each enhance muscle insulin sensitivity as well as other cardiometabolic parameters, they disparately alter amino and citric acid metabolites as well as the lipidome, linking these metabolomic changes independently to the improvement of cardiometabolic risks with each exercise training mode. These findings reveal an important layer of the unique exercise mode–dependent changes in muscle metabolism, which may eventually lead to more informed exercise prescription for improving SI.
Toxicities of CAR T-cell therapy: a review of current literature
Shah, Syed Muhammad Ismail , Rani, Anooja , Kazmi, Sana , Savul, Ilma Saleh , Ukrani, Janta, Khan, Farmanullah , Hasan, Chaudhary A., Rathore, Navin, Syed, Maria , Keswani, Shiwani, Surkasha, FNU, Mal, Doongro, Kumar, Dileep , Asghar, Muhammad Sohaib

Mayo Clinic

Annals of Medicine & Surgery | October 20, 2023 | Volume: 85 | Issue: 12 | Pages: 6013-6020

10.1097/ms9.0000000000001375 | PMID 38098580 Get It

The chimeric antigen receptor (CAR) design, first invented by Zelig Eshhar, paved the way for the use of genetically modified T-cells in targeted therapy against cancer cells. Since then, it has gone through many generations, especially with the integration of co-stimulation in the second and third-generation CARs. However, it also mounts a hyperactive immune response named as cytokine release syndrome with the release of several cytokines eventually resulting in multiple end-organ toxicities. The severity of cytokine release syndrome depends upon certain factors such as the tumor burden, choice of co-stimulation, and degree of lymphodepletion, and can manifest as pulmonary edema, vascular leak, renal dysfunction, cardiac problems, hepatic failure, and coagulopathy. Many grading criteria have been used to define these clinical manifestations but they lack harmonization. Neurotoxicity has also been significantly associated with CAR T-cell therapy but it has not been studied much in previous literature. This review aims to provide a comprehensive account of the clinical manifestations, diagnosis, management, and treatment of CAR T-cell associated neurotoxicity.
Variations in Administrative Approvals During the COVID-19 Pandemic at Participating Sites in the Society of Critical Care Medicine Discovery Network Viral Infection and Respiratory Illness Universal Study: COVID-19 Registry: A Cross-Sectional Study
Bansal, Vikas , Sharma, Mayank , Qamar, Shahraz , Lyman, Susan K., Kumar, Vishakha K. , Bogojevic, Marija , Nawathe, Pooja , Boman, Karen , Retford, Lynn, Group, for the Society of Critical Care Medicine (SCCM) Discovery Viral Infection and Respiratory Illness Universal Study (VIRUS): COVID-19 Registry Investigator, Tawheed, Ahmed , Lyman, Susan, Singh, Romil , Bansal, Vikas , Deo, Neha , Walkey, Allan J. , Tekin, Aysun , Gajic, Ognjen , Kashyap, Rahul , Group, for the Society of Critical Care Medicine (SCCM) Discovery Viral Infection and Respiratory Illness Universal Study (VIRUS): COVID-19 Registry Investigator

Mayo Clinic

Critical Care Explorations | October 19, 2023 | Volume: 4 | Issue: 12 | Pages: e0822

10.1097/cce.0000000000000822 | PMID 36567789 Get It

OBJECTIVES: There is a paucity of literature regarding administrative approvals required for clinical studies during a pandemic. We aimed to evaluate variation in duration of administrative approvals within the Viral Infection and Respiratory illness Universal Study (VIRUS): A Global COVID-19 Registry. DESIGN, SETTING, AND SUBJECTS: Survey analysis of 188 investigators who participated in the VIRUS: COVID-19 registry, a prospective, observational global registry database of 287 sites. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: For each study site approved through December 8, 2020, we assessed the duration in days: 1) from institutional review board (IRB) submission to IRB approval, 2) from IRB approval to Research Electronic Data Capture (REDCap) access, 3) from REDCap access to first patient data entry in REDCap, and 4) total duration from IRB submission to first patient data entry in REDCap. Analysis of variance and Wilcoxon rank-sum test were used to compare time durations. Of 287 sites, 188 sites (United States = 155, non-United States = 33) provided complete administrative data. There was considerable variability in duration from IRB submission to first patient data entry with median (interquartile range) of 28 days (16–50 d), with differences not significantly different by country (United States: 30 [17–50] vs non-United States: 23 d [8–46 d]; p = 0.08) or previous “multisite trial experience” (experienced: 27 [15–51] vs not experienced: 29 d [13–47 d]; p = 0.67). The U.S. sites had a higher proportion of female principal investigators (n = 77; 50%), compared with non-U.S. sites (n = 7; 21%; p = 0.002). Non-U.S. sites had a significantly shorter time to first patient data entry after REDCap access: 7 (1–28) versus 3 days (1–6 d) (p = 0.02). CONCLUSIONS: In this Society of Critical Care Medicine global VIRUS: COVID-19 Registry, we identified considerable variability in time from IRB submission to first patient data entry with no significant differences by country or prior multicenter trial experience. However, there was a significant difference between US and non-U.S. sites in the time from REDCap access to first data entry.
S238 Comparative Analysis of Clostridioides difficile Infection Outcomes in Patient With Solid Organ Transplant vs Without Solid Organ Transplant in the United States
Vikash, Fnu , Kumar, Vikash , Syed, Noor, Taj, Sobaan , Kilani, Yassine , Malik, Talia F. , Hussain, Sana , Vikash, Sindhu, Patel, Sunny , Ali, Hassam , Pan, Chun‐Wei , Osagiede, Osayande , Miranda, Clive Jude

Mayo Clinic

American Journal of Gastroenterology | October 18, 2023 | Volume: 118 | Issue: 10S | Pages: S178-S179

10.14309/01.ajg.0000950592.66136.1c Get It

A systematic review and meta-analysis of new-onset atrial fibrillation in the context of COVID-19
Rathore, Sawai Singh , Atulkar, Akanksha, Remala, Kavya, Corrales, Vanessa Vidaurre, Puar, Ravinderjeet Kaur, Yao, Sem Josue Nsanh, Ganipineni, Vijaya Durga Pradeep, Patel, Nirmal , Thota, Naganath, Deshmukh, Abhishek , Farrukh, Ameer Mustafa , Kumar, Ashish

Mayo Clinic

No container title available | October 18, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.169765039.99940242/v1 Get It

Background: New-onset atrial fibrillation (NOAF) in COVID-19 raises significant clinical and public health issues. This systematic review and meta-analysis aims to compile and analyze the current literature on NOAF in COVID-19 and give a more comprehensive understanding of the prevalence and outcomes of NOAF in COVID-19. Methods: A comprehensive literature search was carried out using several databases. The random effect model using inverse variance method and DerSimonian and Laird estimator of Tua2 was used to calculate the pooled prevalence and associated 95% confidence interval (CI). Results for outcome analysis were presented as odds ratios (ORs) with 95% CI and pooled using the Mantel-Haenszel random-effects model. Results: The pooled prevalence of NOAF in COVID-19 was 7.8% (95% CI, 6.54% to 9.32%), pooled estimate from 30 articles (81,929 COVID-19 patients). Furthermore, our analysis reported that COVID-19 patients with NOAF had a higher risk of developing severe disease compared with COVID–19 patients without a history of atrial fibrillation (OR= 4.78, 95% CI 3.75 to 6.09) and COVID-19 patients with a history of pre-existing atrial fibrillation (OR= 2.75, 95% CI 2.10 to 3.59) . Similarly, our analysis also indicated that COVID–19 patients with NOAF had a higher risk of all-cause mortality compared with, COVID–19 patients without a history of atrial fibrillation (OOR= 3.83, 95% CI 2.99 to 4.92) and COVID-19 patients with a history of pre-existing atrial fibrillation (OR= 2.32, 95% CI 1.35 to 3.96). The meta-analysis did not reveal any significant publication bias. Conclusion: The results of the current meta-analysis a high prevalence rate of NOAF among COVID-19 patients. Further the study reported higher disease severity with NOAF compared with COVID-19 patients without a history of atrial fibrillation and with a history of atrial fibrillation.
Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma
Fukao, Taro, Chiron, Marielle , Richardson, Paul G. , Atanackovic, Djordje , Chini, Eduardo N. , Velde, Helgi van de , Chini, Eduardo, Bisht, Kamlesh Kumar , Richardson, Paul Gerard Guy , Chng, Wee Joo , Malavasi, Fabio

Mayo Clinic

Cancer Medicine | October 16, 2023 | Volume: 12 | Issue: 20 | Pages: 20332-20352

10.1002/cam4.6619 | PMID 37840445 Get It

AbstractBackgroundCD38 has been established as an important therapeutic target for multiple myeloma (MM), for which two CD38 antibodies are currently approved—daratumumab and isatuximab. CD38 is an ectoenzyme that degrades NAD and its precursors and is involved in the production of adenosine and other metabolites.AimAmong the various mechanisms by which CD38 antibodies can induce MM cell death is immunomodulation, including multiple pathways for CD38‐mediated T‐cell activation. Patients who respond to anti‐CD38 targeting treatment experience more marked changes in T‐cell expansion, activity, and clonality than nonresponders.ImplicationsResistance mechanisms that undermine the immunomodulatory effects of CD38‐targeting therapies can be tumor intrinsic, such as the downregulation of CD38 surface expression and expression of complement inhibitor proteins, and immune microenvironment‐related, such as changes to the natural killer (NK) cell numbers and function in the bone marrow niche. There are numerous strategies to overcome this resistance, which include identifying and targeting other therapeutic targets involved in, for example, adenosine production, the activation of NK cells or monocytes through immunomodulatory drugs and their combination with elotuzumab, or with bispecific T‐cell engagers.
Incidence and Distribution of Various Arterial Territories Involved in Postoperative Neurological Complications in Patients Undergoing Cardiovascular Surgery: A Single Centre Retrospective Analysis
Rahul, Kumar , Kumar, Suresh , Kumar, Satish , Kumar, Bhupendra, Kumar, Sarvesh , Garg, Pankaj , Tewarson, Vivek

Mayo Clinic

Research in Cardiovascular Medicine | October 9, 2023 | Volume: 12 | Issue: 1 | Pages: 26-32

10.4103/rcm.rcm_6_23 Get It

Background: Neurological complications (NCs) (stroke) remain a devastating complication after cardiovascular surgical procedures despite advances in perioperative monitoring and management. The incidence of NC related to cardiovascular surgeries (CS) is comparatively very high and associated with high morbidity and mortality. The aim of this study is to evaluate the overall incidence of neurological complications in adult as well as pediatric patients and various pattern of neurological injury on noncontrast computed tomography head (NCCT) associated with various types of CS. Materials and Methods: We retrospectively analyzed all the NCCT heads of the postoperative cardiovascular surgery patients done in the immediate and early postoperative period (<7 days) who developed postoperative neurological deficits between April 2016 and February 2020. The medical records of all these cardiac surgery patients were analyzed for various variants such as the total number of patients who underwent CS, various types of cardiac surgery done during the study period, demographic information, associated comorbidities, various types of NC, postoperative data and various spectrum of computed tomography (CT) findings in the brain. Results: A total of 12,896 adult and pediatric cardiac surgeries were performed at our institute. Out of these, 1115 patients (8.6%) underwent CT brain for suspected neurological injury. A total of 215 patients (1.6%) had a positive finding on their NCCT head. Out of 215 patients, 148 (68.9%) were adult patients, whereas 67 (31.1%) were pediatric patients. A total of 156 (72.5%) patients had ischemic infarction (stroke), whereas hemorrhagic lesions were present in 59 patients (27.4%). The various types of positive CT scan findings were-156 ischemic infarcts (72.5%), 20 intraparenchymal hemorrhages (9.3%), 16 subdural hemorrhage (7.4%), 15 subarachnoid hemorrhage (6.9%), 01 cerebrovascular thrombosis (0.4%), and 07 intraventricular hemorrhage (3.2%). In an adult patient, pattern of ischemic infarct comprised middle cerebral artery (MCA) territory in 42 patients (41.5%), posterior territory in 34 patients (33.6%), anterior cerebral territory in seven patients (7.0%), multi-territory infracts in 11 patients (11.0%) and global ischemia in six patients (6.0%). Intraparenchymal hemorrhage was present in 17 patients (11.4%). In a pediatric subset of patient, the pattern of ischemic infarct included global hypoxic injury (GHI) in 30 patients (54.5%), posterior cerebral artery territory in nine patients (16.3%), MCA territory in eight patients (14.5%), multi-territory involvement in five patients (9.0%), and anterior cerebral artery territory in three patients (5.4%). In the hemorrhage group, five patients (7.4%) developed subarachnoid hemorrhage (SAH). Conclusion: In an adult patient, subset MCA territory infarcts were common in the infract group, whereas intra parenchymal haemorrhage (IPH) in the hemorrhage group. In the pediatric patient subset, GHI was common in infract group and SAH in hemorrhage group. Moreover, NCCT of the head is very useful in diagnosing early postoperative neurological complications in cardiovascular surgeries and managing the complications accordingly.